Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis

Table 2 Hospital anxiety and depression scale scores and functional assessment of chronic illness therapy-fatigue scores

Instrument/	ETN + MTX	DMARD + MTX	P Value*
Time on therapy	Mean Score (% Improvement from Baseline) (N)
Anxiety Subscale
Baseline	8.27 (0%) (N = 196)	8.19 (0%) (N = 103)
Week 16	5.84 (29.1%) (N = 192)	6.69 (18.5%) (N = 100)	0.026
Depression Subscale
Baseline	7.62 (0%) (N = 196)	7.85 (0%) (N = 103)
Week 16	5.42 (28.7%) (N = 192)	6.56 (16.4%) (N = 100)	0.016
FACIT-Fatigue
Baseline	28.1 (0%) (N = 146)	30.1 (0%) (N = 76)
Week 16	36.2 (28.0%) (N = 143)	33.2 (10.4%) (N = 73)	0.001

Scores at Baseline and Following 16 Weeks of Therapy in Asia-Pacific Rheumatoid Arthritis Patients Treated With ETN + MTX versus DMARD + MTX (Last Observation Carried Forward Analysis).
DMARD: Disease Modifying Antirheumatic Drug; ETN: etanercept; FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy- Fatigue; MTX: methotrexate.
*ANCOVA, considering the factors ‘baseline score + therapy + country’.

ISSN: 1471-2474